The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Duodenal Niemann-Pick C1-like 1 expression was negatively correlated with liver X receptor expression in nonalcoholic fatty liver disease

  • Ahn, Sang Bong (Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine) ;
  • Jun, Dae Won (Department of Internal Medicine, Hanyang University School of Medicine) ;
  • Jang, Kiseok (Department of Pathology, Hanyang University School of Medicine) ;
  • Lee, Byung Hoon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Shin, Kye Jung (College of Pharmacy, The Catholic University of Korea)
  • Received : 2017.02.27
  • Accepted : 2017.11.03
  • Published : 2019.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Intestinal cholesterol absorption includes intestinal Niemann-Pick C1-like 1 (NPC1L1) and is an important target pathway in nonalcoholic fatty liver disease (NAFLD). We investigated the expression of NPC1L1 and its correlation with liver X receptor (LXR) expression in peripheral mononuclear (PMN) cells in patients with NAFLD. Methods: We evaluated intestinal expression of NPC1L1 in 25 NAFLD patients and 28 healthy controls. We calculated the mRNA expression levels of LXR and farnesoid X receptor (FXR), which are master players of cholesterol metabolism in PMN cells. The protein expression of ABCA1, ABCG5/8, NPC1L1, SREBP, LXR, FXR, and CD36 was measured on tissue samples from the duodenum and ileum. Results: The expression of LXR (p = 0.01) and FXR (p = 0.03) in PMN cells was increased in the NAFLD group compared to the control group. Duodenal NPC1L1 decreased in the NAFLD group compared to the healthy controls (3.38 ± 1.4 vs. 2.42 ± 1.2, p = 0.05). NPC1L1 expression in the duodenum was negatively correlated with LXR expression in PMN cells. Expression of LXR and FXR in the ileum was also negatively correlated with the expression of LXR in PMN cells. Conclusions: Duodenal NPC1L1 expression was decreased in NAFLD and was negatively correlated with LXR expression in PMN cells.

Keywords

Acknowledgement

This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A121185).

References

  1. Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Clin Pract 2004;58:859-866. https://doi.org/10.1111/j.1742-1241.2004.00351.x
  2. Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013;19:210-215. https://doi.org/10.3350/cmh.2013.19.3.210
  3. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204. https://doi.org/10.1126/science.1093131
  4. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-33592. https://doi.org/10.1074/jbc.M405817200
  5. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005;102:8132-8137. https://doi.org/10.1073/pnas.0500269102
  6. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009;297:E1030-E1038. https://doi.org/10.1152/ajpendo.00343.2009
  7. Ahn SB, Jang K, Jun DW, Lee BH, Shin KJ. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:2975-2982. https://doi.org/10.1007/s10620-014-3289-x
  8. Moschetta A. Nuclear receptors and cholesterol metabolism in the intestine. Atheroscler Suppl 2015;17:9-11. https://doi.org/10.1016/S1567-5688(15)50003-2
  9. Bonamassa B, Moschetta A. Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol Metab 2013;24:120-128. https://doi.org/10.1016/j.tem.2012.10.004
  10. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-1870. https://doi.org/10.1126/science.294.5548.1866
  11. Rebe C, Raveneau M, Chevriaux A, et al. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ Res 2009;105:393-401. https://doi.org/10.1161/CIRCRESAHA.109.201855
  12. DiBlasio-Smith EA, Arai M, Quinet EM, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med 2008;6:59. https://doi.org/10.1186/1479-5876-6-59
  13. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-729. https://doi.org/10.1148/radiology.137.3.6934563
  14. Bydder GM, Chapman RW, Harry D, Bassan L, Sherlock S, Kreel L. Computed tomography attenuation values in fatty liver. J Comput Tomogr 1981;5:33-35. https://doi.org/10.1016/0149-936X(81)90054-0
  15. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008;28:1296-1297. https://doi.org/10.1161/ATVBAHA.108.165803
  16. Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011;54:153-159.
  17. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010;40:566-573. https://doi.org/10.1111/j.1872-034X.2010.00644.x
  18. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-107. https://doi.org/10.1007/s00535-010-0291-8
  19. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of non-alcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-348. https://doi.org/10.3350/cmh.2013.19.4.325
  20. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443. https://doi.org/10.1056/NEJMoa0800742
  21. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 2008;28:448-454. https://doi.org/10.1161/ATVBAHA.107.160465
  22. Duval C, Touche V, Tailleux A, et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006;340:1259-1263. https://doi.org/10.1016/j.bbrc.2005.12.137
  23. Lo Sasso G, Murzilli S, Salvatore L, et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab 2010;12:187-193. https://doi.org/10.1016/j.cmet.2010.07.002
  24. Vik-Mo AO, Ferno J, Skrede S, Steen VM. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009;9:10.
  25. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012;13:213-224. https://doi.org/10.1038/nrm3312
  26. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445. https://doi.org/10.1016/j.jhep.2009.05.023
  27. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-112. https://doi.org/10.1148/radiol.2391050361
  28. Masson CJ, Plat J, Mensink RP, et al. Fatty acid- and cholesterol transporter protein expression along the human intestinal tract. PLoS One 2010;5:e10380. https://doi.org/10.1371/journal.pone.0010380

Cited by

  1. Dietary fatty acids and CD36-mediated cholesterol homeostasis: potential mechanisms vol.34, pp.1, 2019, https://doi.org/10.1017/s0954422420000128